Clinical Trial Update: A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection [Phase 3]

View source ↗

Summary

This document reports a termination of a long-term follow-up Phase 3 study of a regimen containing odalasvir, AL-335, with or without simeprevir for Hepatitis C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• AL-335 (AL-335)
• Odalasvir (odalasvir)
• Simeprevir (simeprevir)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hepatitis C | Phase 3 | Status: TERMINATED